UTHR News Alert United Therapeutics Corp (UTHR) 130.22 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
United Therapeutics Corp (UTHR) 130.22 $UTHR

United Therapeutics progresses on expanded label for Remodulin
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 11:13AM CST

MDT: 74.08 (+0.31), UTHR: 130.22 (+2.40)

United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin
PR Newswire - Wed Dec 24, 10:26AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.
MDT: 74.08 (+0.31), UTHR: 130.22 (+2.40)

Actelion Submits New Drug Application for Uptravi in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:35PM CST
Actelion Ltd. (ALIOF) announced the submission of a new drug application to the FDA for its pulmonary arterial hypertension candidate, Uptravi (selexipag).
ANIP: 55.24 (+1.79), UTHR: 130.22 (+2.40)

Fed's Patience Puts Bulls In A Hurry
Scott Martindale - Seeking Alpha - Tue Dec 23, 11:08AM CST
U.S. stocks found support once again last week and rallied on strong volume. Of course, the main catalyst was the FOMC policy statement on Wednesday that maintained its dovish language with a pledge of considerable time before raising the fed funds...
DEF: 38.15 (-0.96), NFO: 49.34 (-0.38), PNW: 69.59 (+1.41), UTHR: 130.22 (+2.40), ED: 66.91 (+0.90), IBB: 299.80 (+5.12), LUV: 41.66 (+0.68), IYZ: 29.52 (-0.18), LYB: 81.31 (-0.89), SPY: 207.77 (+0.02), IDU: 120.07 (+1.13), IYW: 106.52 (-0.41), IYK: 106.07 (-0.66), IYJ: 108.21 (-0.61), IYH: 144.69 (+0.58), BCR: 169.10 (-0.44), IYM: 83.15 (-0.74), IYC: 137.57 (-0.15), NXPI: 76.75 (+0.48), FUTY: 31.00 (+0.60), IYF: 91.09 (-0.41), IYE: 45.37 (-0.54), PYZ: 53.07 (+0.10), SHW: 264.55 (+1.46), KNOW: 69.79 (+0.15)

United Therapeutics Lung Drug Keeps Going And Going
at Investor's Business Daily - Fri Dec 19, 4:20PM CST
Big-cap biotech and IBD 50 stock United Therapeutics has a history of confounding expectations -- in a good way. Almost exactly a year ago, the Food and Drug Administration approved Orenitram, a pill for treating pulmonary arterial hypertension...
MDT: 74.08 (+0.31), GILD: 91.29 (+1.84), PFE: 31.42 (-0.03), UTHR: 130.22 (+2.40), NVS: 93.91 (+0.66)

Executives on the move at United Therapeutics
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:12AM CST

UTHR: 130.22 (+2.40)

United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change
PR Newswire - Wed Dec 17, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today two senior executive promotions as well as changes to Martine Rothblatt, Ph.D's compensation program.
UTHR: 130.22 (+2.40)

Additions/deletions from Nasdaq's Q-50 Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:54AM CST

GLNG: 36.67 (+1.15), MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), NUAN: 14.37 (-0.09), UTHR: 130.22 (+2.40), FSLR: 43.67 (-0.39), QQQ: 104.30 (+0.09), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), MPEL: 24.81 (+0.20), EXPE: 89.01 (+0.09), FFIV: 135.11 (+1.17), SSYS: 81.12 (+0.24), CAR: 64.23 (-0.25), JD: 24.61 (-0.12), SPLK: 61.49 (-0.11), MELI: 127.84 (+1.30), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08)

Quarterly Changes to the NXTQ Index
GlobeNewswire - Mon Dec 15, 6:20AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, December 22, 2014.
MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), EA: 48.06 (+0.23), UTHR: 130.22 (+2.40), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), SSYS: 81.12 (+0.24), FFIV: 135.11 (+1.17), MPEL: 24.81 (+0.20), AAL: 51.43 (+1.22), CAR: 64.23 (-0.25), NWS: 14.92 (-0.07), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08), GLNG: 36.67 (+1.15), NUAN: 14.37 (-0.09), FSLR: 43.67 (-0.39), LRCX: 81.13 (-0.44), EXPE: 89.01 (+0.09), SPLK: 61.49 (-0.11), JD: 24.61 (-0.12), MELI: 127.84 (+1.30), NDAQ: 48.74 (-0.40)

United Therapeutics: Will It Pass Peers In 2015?
at Investor's Business Daily - Fri Dec 12, 5:11PM CST
Biomed company United Therapeutics is in a strong industry group, and that's a problem. United Therapeutics' (UTHR) three-year earnings growth rate is 26%, good enough for an EPS Rating of 89. However, in a leading group, "good enough" isn't good...
BIIB: 340.89 (+5.13), UTHR: 130.22 (+2.40), ALXN: 181.96 (+3.09), TEVA: 57.09 (+0.33), CELG: 109.60 (+3.48)

Can United Therapeutics find a remedy for recent resistance?
at Investor's Business Daily - Thu Dec 11, 10:48AM CST
Today we'll look at United Therapeutics (UTHR), which develops therapies to treat pulmonary arterial hypertension, cancer and some of the most complicated viral diseases. Key Fundamentals After a sharp decline in earnings growth for several quarters,...
UTHR: 130.22 (+2.40)

Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Thu Dec 11, 7:05AM CST
United Therapeutics (NASDAQ:UTHR) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $131.51 on volume of 653,000 shares, below average daily volume of 670,000. Based on a current price of $131.51, United Therapeutics is currently 3.7% above its average consensus analyst price target of $126.62. The stock should discover initial support at its 50-day moving average (MA) of $128.48 and subsequent support at its 200-day MA of $106.56.
UTHR: 130.22 (+2.40)

Stocks Fall To Session Lows: GoPro Gives Up More Ground
at Investor's Business Daily - Mon Dec 08, 12:25PM CST
Stocks were near session lows in early afternoon trading as oil prices fell hard again. The Nasdaq lost 0.5%, the S&P 500 fell 0.4% and the Dow Jones industrial average gave up 0.4% also. Nasdaq and NYSE volume was tracking slightly higher than...
AMBA: 52.05 (+0.72), GPRO: 66.41 (+4.87), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), UTHR: 130.22 (+2.40), MCD: 93.83 (-0.39), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST

MSTX: 0.46 (unch), GILD: 91.29 (+1.84), UTHR: 130.22 (+2.40), GSK: 42.85 (+0.11), ARNA: 3.57 (-0.01)

Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 340.89 (+5.13), UTHR: 130.22 (+2.40)

Stock Market Today: Top Biotech Is Near Buy Point
at Investor's Business Daily - Wed Nov 26, 4:40PM CST
Many leading stocks have risen out of buying range since a new market uptrend began last month, but a number are still working on bases. United Therapeutics (UTHR), which develops treatments for cardiovascular and infectious diseases as well as for...
UTHR: 130.22 (+2.40), GIII: 99.53 (+1.82), CAR: 64.23 (-0.25), CP: 194.85 (-0.13)

United Therapeutics Earnings In Retrospect: Down 3.9% in the Last 20 Days (UTHR)
Comtex SmarTrend(R) - Mon Nov 17, 3:24PM CST
20 days ago, on October 28th, 2014, United Therapeutics (NASDAQ:UTHR) reported its earnings. Analysts, on average, expected earnings of $2.75 per share on sales of $335.1 million. The company actually reported EPS of $3.91 on sales of $330.0 million, beating EPS estimates by $1.16 and missing revenue estimates by $5.2 million. Since the company's report, shares of United Therapeutics have fallen from $130.49 to $125.43, representing a loss of 3.9% in the past 20 days.
UTHR: 130.22 (+2.40)

United Therapeutics appoints Professor Katherine J. Klein to board
M2 - Thu Nov 13, 7:08AM CST
Biotechnology company United Therapeutics (NasdaqGS:UTHR) stated on Thursday that Professor Katherine J. Klein, PhD has been elected as an independent director to its board of directors with effect from 11 November 2014.
UTHR: 130.22 (+2.40)

Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors
PR Newswire - Thu Nov 13, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today the appointment of Professor Katherine J. Klein, Ph.D., of The Wharton School of the University of Pennsylvania to its Board of Directors as an independent director. The appointment is effective as of November 11, 2014.
UTHR: 130.22 (+2.40), SCHW: 30.67 (+0.01)

United Therapeutics Earnings In Retrospect: Down 4.8% in the Last 13 Days (UTHR)
Comtex SmarTrend(R) - Mon Nov 10, 12:57PM CST
When United Therapeutics (NASDAQ:UTHR) reported earnings a week ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $2.75 on sales of $335.1 million. United Therapeutics actually reported earnings of $3.91 per share on sales of $330.0 million, beating EPS estimates by $1.16 and missing revenue estimates by $5.2 million. Shares of United Therapeutics have slipped from $130.49 to $124.21, representing a loss of 4.8%, since the company reported earnings 13 days ago.
UTHR: 130.22 (+2.40)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 81

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Join Flywire Corporation Securities Class Action

Updated Category News Views 219

Investors Urged to Join Flywire Corporation Securities Class Action The recent developments surrounding Flywire Corporation (NASDAQ: FLYW) have captured the attention of investors, especially those who purchased securities during the specified period. The Rosen Law Firm, known for championing investor rights, is taking the lead in facilitating a securities fraud lawsuit...

Continue Reading
Unicycive Therapeutics Faces Investigation Over Stock Concerns

Updated Category News Views 231

Unicycive Therapeutics Under Investigation for Securities Fraud In recent developments, Pomerantz LLP has initiated an investigation into the possible fraudulent activities involving Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The inquiry focuses on whether the company and its executives may have violated securities laws, an issue that could have implications for many...

Continue Reading
Investors Urged to Act: Join Wolfspeed's Upcoming Class Action

Updated Category News Views 313

Overview of Wolfspeed's Class Action Wolfspeed, Inc. investors are encouraged to take action regarding their stakes in the company as a class action lawsuit surfaces. The Rosen Law Firm, a reputable entity specializing in investor rights, sets a significant deadline for participation in this case. It’s essential for anyone who purchased shares within the specified...

Continue Reading
Pacsun Champions Co-Creation at Music's Grandest Stage

Updated Category News Views 194

Pacsun Champions Co-Creation at Music's Grandest Stage Youth Retailer Debuts Co-Branded Merchandise and Artist Performances As Grammy Weekend celebrates the top talents in music, Pacsun embraces the opportunity to highlight the emerging artists and professionals shaping the future of music. Their approach emphasizes co-creation, access, and cultural participation, crucial...

Continue Reading
Vistra Corp Enhances Financial Stability with Credit Facility Boost

Updated Category News Views 134

Vistra Corp Strengthens Financial Flexibility In a strategic move to enhance its financial flexibility, Vistra Corp. (NYSE:VST), known for delivering electric services, has taken steps to amend its credit agreement. The changes not only extend the maturity date of its credit facility but also expand its borrowing capabilities. This adjustment, effective October 2, 2024,...

Continue Reading